|
Duodenal Ulcer
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population.
|
22387998 |
2012 |
|
Malignant neoplasm of breast
|
0.060 |
Biomarker
|
disease |
BEFREE |
In addition, LY6K is involved in tamoxifen resistance in breast cancer.
|
30655778 |
2019 |
|
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Lymphocyte antigen 6 family member K (LY6K) is upregulated in a number of types of cancer and promotes tumor cell proliferation and metastasis.
|
30655778 |
2019 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
In addition, LY6K is involved in tamoxifen resistance in breast cancer.
|
30655778 |
2019 |
|
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
MiR-500a-3p suppresses cell proliferation, invasion and metastasis formation in vivo by targeting the LY6K. miR-500a-3p acts as a tumor suppressor in NSCLC partially via down-regulation of LY6K expression and for NSCLC intervention and suggests a potential therapeutic target for NSCLC intervention.
|
30249107 |
2018 |
|
Malignant neoplasm of breast
|
0.060 |
Biomarker
|
disease |
BEFREE |
Finally, we observed an inverse correlation between LY6K and ERα in primary breast cancer samples.
|
27304060 |
2016 |
|
Malignant neoplasm of breast
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Here we report increased expression of Ly6K/E in human breast cancer specimens correlates with poor overall survival, with an additional specific role for Ly6E in poor therapeutic outcomes.
|
27197181 |
2016 |
|
Malignant neoplasm of breast
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
LY6K also was upregulated in breast cancer patients with distant metastases than those without distant metastases, downregulating E-cadherin expression.
|
27494879 |
2016 |
|
Neoplasm Metastasis
|
0.060 |
GeneticVariation
|
phenotype |
BEFREE |
Taken together, breast cancer risk and metastasis were significantly associated with not only LY6K expression, but also methylation of CGI shore which induced by SNP242 mutation.
|
27494879 |
2016 |
|
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
In this study, we found that lymphocyte antigen 6 complex (LY6K), which is a member of the Ly-6/μPAR superfamily and related to breast cancer progression and metastasis, is inversely correlated with ERα expression.
|
27304060 |
2016 |
|
Breast Carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Here we report increased expression of Ly6K/E in human breast cancer specimens correlates with poor overall survival, with an additional specific role for Ly6E in poor therapeutic outcomes.
|
27197181 |
2016 |
|
Breast Carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
LY6K also was upregulated in breast cancer patients with distant metastases than those without distant metastases, downregulating E-cadherin expression.
|
27494879 |
2016 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Finally, we observed an inverse correlation between LY6K and ERα in primary breast cancer samples.
|
27304060 |
2016 |
|
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
LY6K is a cancer biomarker and a therapeutic target that induces invasion and metastasis.
|
22988241 |
2012 |
|
Malignant neoplasm of breast
|
0.060 |
Biomarker
|
disease |
BEFREE |
Our results suggest that LY-6K meaningfully participates in breast cancer cell metastasis by influencing cell migration and invasion through the Ras/ERK pathway.
|
19639180 |
2009 |
|
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Our results suggest that LY-6K meaningfully participates in breast cancer cell metastasis by influencing cell migration and invasion through the Ras/ERK pathway.
|
19639180 |
2009 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Our results suggest that LY-6K meaningfully participates in breast cancer cell metastasis by influencing cell migration and invasion through the Ras/ERK pathway.
|
19639180 |
2009 |
|
Malignant neoplasm of breast
|
0.060 |
Biomarker
|
disease |
BEFREE |
These results suggest that LY-6K is not only a target antigen for HNSCC but also a significant new molecular marker for diagnosis and gene therapy in patients with breast cancer.
|
17089039 |
2006 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
These results suggest that LY-6K is not only a target antigen for HNSCC but also a significant new molecular marker for diagnosis and gene therapy in patients with breast cancer.
|
17089039 |
2006 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
These findings suggest that the overexpression of LY6K suppresses T cell development, and that LY6K is a potential therapeutic target for cancer.
|
30655778 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Lymphocyte antigen 6 family member K (LY6K) is upregulated in a number of types of cancer and promotes tumor cell proliferation and metastasis.
|
30655778 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
These findings suggest that the overexpression of LY6K suppresses T cell development, and that LY6K is a potential therapeutic target for cancer.
|
30655778 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Clinical analysis indicated that miR-500a-3p and LY6K were related to tumor differentiation, lymph node metastasis and TNM staging in NSCLC patients.
|
30249107 |
2018 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The functions of miR-500a-3p and LY6K in proliferation/invasion and lung metastasis formation were assessed by CCK8, Transwell assay and subcutaneous tumor model in nude mice, respectively.
|
30249107 |
2018 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Furthermore, xenograft tumor volumes from LY6K knockdown nude mice were reduced than those of mice treated with control lentivirus.
|
27494879 |
2016 |